Increased Regulatory consideration of RWE in NDA/BLA submissions
The increased Regulatory consideration of RWE in NDA/BLA submissions represents a fundamental shift toward a more patient-centric, evidence-based approach to drug evaluation. This approach has the potential to expedite access to life-saving therapies, particularly for those facing rare diseases and unmet medical needs.